Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term prostate-specific antigen. Found 21 abstracts

no pagination
Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M, Lawton CA, Sandler HM. Impact of Biochemical Failure Classification on Clinical Outcome: A Secondary Analysis of Radiation Therapy Oncology Group 9202 and 9413. Cancer. 2015 Mar;121(6):844-52.   PMCID: 4657945
Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. BJU international. 2014 May;113(5B):E150-E156.   PMCID: PMC 3830710
Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU international. 2014 May;113(5B):E106-E111.
Negin BP, Cohen SJ. Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges. Current treatment options in oncology. 2010 Jun;11(1-2):1-13.   PMCID: not NIH funded
Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation Therapy After Radical Prostatectomy: Impact on Metastasis and Survival. Journal of Urology. 2009 Dec;182(6):2708-14.
Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detection and Prevention. 2007 Jan;31(1):50-8.
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. International Journal of Radiation Oncology Biology Physics. 2007 Feb;67(2):327-33.
Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2005 Dec;63(5):1455-62.
Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?. International Journal of Radiation Oncology Biology Physics. 2005 Mar 15;61(4):1003-10.
Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. Journal of Clinical Oncology. 2005 Nov 10;23(32):8204-11.
Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. Journal of Urology. 2005 Mar;173(3):797-802.
Weinfurt KP, DePuy V, Castel LD, Sulmasy DP, Schulman KA, Meropol NJ. Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer. 2005 Jan;103(1):140-7.
Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.
Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics. 2002 Aug;53(5):1097-105.
Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY, Sauter ER, Diamandis EP. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. British Journal of Cancer. 2000 Jan;82(2):361-7.
Horwitz EM, Hanlon AL, Pinover WH, Hanks GE. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. International Journal of Radiation Oncology Biology Physics. 1998 Jun;41(3):519-23.
Freedman GM, Hanlon AL, Lee WR, Hanks GE. Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. International Journal of Radiation Oncology Biology Physics. 1996 May;35(2):243-50.
Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival. Journal of Urology. 1996 Aug;156(2):450-3.
Corn BW, Hanks GE, Lee WR, Bonin SR, Hudes G, Schultheiss T. Prostate-Specific Antigen Density Is Not an Independent Predictor of Response for Prostate-Cancer Treated by Conformal Radiotherapy. Journal of Urology. 1995 Jun;153(6):1855-9.
Hanks GE. Are Only Low Pretreatment Psa Patients Curable. International Journal of Radiation Oncology Biology Physics. 1995 May 15;32(2):545-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term prostate-specific antigen

prostate-specific antigen prostate cancer radiotherapy prostatic neoplasms radical prostatectomy cancer external-beam radiotherapy antigen carcinoma irradiation TRIAL prostate MORTALITY doubling time dose FOLLOW-UP american society breast cancer local recurrence conformal radiation-therapy screening Urology & Nephrology therapy follow-up informed-consent prostatectomy definitive radiotherapy fibroblast growth factor therapeutic misconception monoclonal- iii randomized trial human glandular kallikrein 2 radiology therapeutic radiology gene-expression SERVICES TASK-FORCE I-125 psa doubling time breast-cancer Male less-than-or-equal-to-10 risk receptors GENOME-WIDE ASSOCIATION KeyWords Plus: pelvic irradiation neoplasm antigens predict pathological stage three-dimensional conformal radiotherapy dose-escalation oncology recursive partitioning analysis escalation prostate-specific antigen failure antigen era family history phase-iii trial survey human glandular kallikrein messenger-rna FIBROBLAST-GROWTH-FACTOR Kallikreins postoperative radiotherapy adenocarcinoma conformal radiotherapy clinical-significance predictive markers surrogate end point gleason score isotope dose-response SOCIETY assessing biochemical failure Middle Aged RESIDUAL CANCER prognostic factor radiation therapy blood 80 and over Aged young men AMERICAN SOCIETY basic randomized clinical-trial serum kallikrein gene family radiation-therapy IRRADIATION antigen levels positron-emission-tomography enhance adjustment pathology 1st-line treatment psa stage tie quality-of-life mortality immunomagnetic enrichment predicting recurrence consensus definition RESPONSE RATES Proportional Hazards Models Prostatic Neoplasms radiation treatment RADIOLOGY GUIDELINE WOMEN antibodies genetics SUSCEPTIBILITY androgen deprivation therapy Treatment Outcome cytology locally advanced-carcinoma CYTOLOGY prognostic numeracy BRACHYTHERAPY Radiotherapy adjuvant therapy RADIATION-THERAPY pathological stage S phase fraction benefit recurrence prognostic-factors Prognosis neoadjuvant brachytherapy proteins nipple aspirate communication Phase I clinical trials-decision making-informed consent-neoplasms-patient participation-perception-physician-patient relations-truth disclosure outcomes cross-reactivity androgen deprivation biochemical control nerve-sparing prostatectomy diagnosis Treatment Failure nipple aspirate fluid peripheral-blood DNA index treatment failure fluid postprostatectomy radiotherapy stage LOCI ANGIOGENIC FACTORS Prostate-Specific Antigen salvage radiotherapy
Last updated on Friday, August 14, 2020